Background: Staphylococcus aureus is a gram-positive bacterium that can cause various diseases and infections. Penicillin and methicillin are examples of β-lactam antibiotics, the first line of defense against Staphylococcus aureus infections. Methicillin-Resistant Staphylococcus aureus (MRSA) is still one of the leading causes of hospital-acquired infections associated with morbidity, mortality, and cost. MRSA can be hospital-acquired (HA-MRSA) or community-associated (CA-MRSA) infections. The main objective of this study is to screen MRSA among HA-MRSA to determine the prevalence of antibiotic susceptibility patterns of MRSA among patients. Furthermore, we identify the mecA gene, which produces a penicillin-binding protein (PBP2a) with a low affinity for β-lactam antibiotics. Methods: This study was done on the patients of Kathmandu Model Hospital, Nepal, and the samples were processed at the Microbiology laboratory of Kathmandu Model Hospital. Data analyses were done from Microsoft Excel and GraphPad Prism. DNA extraction was done from the classical CTAB method with minor modifications, and mecA gene-specific primers were used to detect the gene in the samples. Results: Out of 4383 samples, 848 (21.00%) samples have growth, and 190(22.4%) were Staphylococcus aureus. Among Staphylococcus aureus 52 (27.36%) were Methicillin resistant Staphylococcus aures. Antibiotic susceptibility tests were done to characterize MRSA isolates. Most of the isolates were resistant to Amikacin (69.25%), followed by Ampicillin (53.8%), Chloramphenicol (78.84%), Cotrimoxazole (53.8%), Gentamycin (67.3%), Ofloxacin (15.39%), Erythromycin (71.15%) Vancomycin and Teicoplanin (3.84%). In our study, 50 (96.15%) out of 52 MRSA showed the mecA gene, while 3.85% showed the absence of the mecA gene. Conclusions: The frequency of MRSA infections in HA-MRSA was comparatively high, with a greater abundance of the mecA gene that confers the resistance. Regular surveillance of HA-MRSA and genetic profiling of the mecA gene are essential for reducing MRSA infection.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The ethical approval for this study was approved by the Institutional Review Committee (IRC) of the Public Health Concern Trust, Nepal (phect-NEPAL) to conduct the research project at phect-NEPAL/Kathmandu Model Hospital under IRC application number: 006-2020.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors